Harbour BioMed, batoclimab, generalized myasthenia gravis, gMG, NMPA approval, China drug approval, FcRn inhibitor, autoimmune disease, Phase 3 clinical trial, monoclonal antibody

Cambridge, Massachusetts, USA; Rotterdam, Netherlands; and Shanghai, China, October 22, 2026 Harbour BioMed has received approval from China’s National...